| Title |
Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study
|
|---|---|
| Published in |
Diabetologia, November 2016
|
| DOI | 10.1007/s00125-016-4163-5 |
| Pubmed ID | |
| Authors |
Megan L. Gow, Louise A. Baur, Nathan A. Johnson, Chris T. Cowell, Sarah P. Garnett |
| Abstract |
The aim of the study was to investigate whether a very-low-energy diet (VLED) is a feasible and acceptable treatment option for type 2 diabetes in children and adolescents, and whether adherence can lead to rapid weight loss, reversal of type 2 diabetes and reduced liver fat as seen in adult studies. Eight participants with type 2 diabetes and obesity, aged 7-16 years, non-medicated (n = 1) or treated with metformin (n = 7) and in some cases insulin (n = 3), followed a VLED (<3360 kJ/day) for 8 weeks, then transitioned to a hypocaloric diet (∼6300 kJ/day) that they followed to 34 weeks. HbA1c, fasting glucose and 2 h post-glucose load plasma glucose (2hG) were determined from fasting blood and an OGTT. Liver fat concentration was quantified using proton magnetic resonance spectroscopy. Adherence was defined as ≥5% weight loss during the 8 week VLED. Adherers (n = 5) and non-adherers (n = 3) had median weight loss of 7.5% and 0.5%, respectively, at 8 weeks. Overall, HbA1c (mean [SE] 8.1% [0.7%] to 6.6% [0.5%]; p = 0.004) and 2hG (15.6 [1.6] mmol/l to 11.3 [1.0] mmol/l; p = 0.009) were significantly reduced at 8 weeks compared with baseline. Liver fat was also significantly reduced from baseline (14.7% [2.2%]) to 8 weeks (5.8% [1.7%]; p = 0.001). Only three out of eight participants met non-alcoholic fatty liver disease (NAFLD) criteria (≥5.5%) at 8 weeks, compared with eight out of eight at baseline. The three participants on insulin therapy at baseline were able to cease therapy during the 8 week VLED. At 34 weeks, adherers (n = 5) achieved 12.3% weight loss, none met NAFLD criteria and four did not meet American Diabetes Association criteria for type 2 diabetes. A VLED appears to be a feasible treatment option for some youth with type 2 diabetes on metformin therapy. Youth who agree to participate and adhere to a VLED achieve rapid weight loss, dramatic reductions in liver fat and reversal of type 2 diabetes. This highlights the capacity of a VLED to be used as a first-line treatment option in newly diagnosed youth. A larger trial with a control group and longer follow-up will be required to encourage a change in standard treatment. Australian New Zealand Clinical Trial Registration Number (ACTRN) ACTRN12616000375459 ( www.ANZCTR.org.au/ACTRN12616000375459.aspx ). |
X Demographics
The data shown below were collected from the profiles of 61 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 9 | 15% |
| Canada | 5 | 8% |
| Spain | 4 | 7% |
| Sweden | 4 | 7% |
| United States | 3 | 5% |
| Mexico | 2 | 3% |
| Australia | 1 | 2% |
| Brazil | 1 | 2% |
| India | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 29 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 39 | 64% |
| Scientists | 12 | 20% |
| Practitioners (doctors, other healthcare professionals) | 10 | 16% |
Mendeley readers
The data shown below were compiled from readership statistics for 182 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | <1% |
| Unknown | 181 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 26 | 14% |
| Student > Master | 25 | 14% |
| Researcher | 19 | 10% |
| Student > Ph. D. Student | 16 | 9% |
| Student > Postgraduate | 12 | 7% |
| Other | 29 | 16% |
| Unknown | 55 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 31% |
| Nursing and Health Professions | 23 | 13% |
| Biochemistry, Genetics and Molecular Biology | 8 | 4% |
| Psychology | 7 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Other | 24 | 13% |
| Unknown | 57 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 60. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2024.
All research outputs
#733,983
of 25,925,760 outputs
Outputs from Diabetologia
#363
of 5,399 outputs
Outputs of similar age
#14,669
of 419,574 outputs
Outputs of similar age from Diabetologia
#11
of 70 outputs
Altmetric has tracked 25,925,760 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,399 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.8. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,574 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.